Built on Iodine’s industry-leading CognitiveML engine, AwareUM emulates clinical thinking to improve productivity and meet medical necessity requirements AUSTIN, Tex. – February 5, 2024 – Iodine Software, a leading healthcare enterprise AI software company, today announced the launch of AwareUM, its newest software solution that helps hospitals streamline their utilization management programs. This launch highlights Iodine's prowess in harnessing artificial intelligence to augment scarce clinical resources, streamlining workflows that were once considered resistant to automation due to the indispensable role of clinical, human judgment. “The debut of AwareUM reaffirms Iodine’s position at the forefront of innovation, signaling the evolution of our business to empower the nation’s leading health systems in navigating the entire clinical revenue cycle,” said William Chan, co-founder and CEO, of Iodine. “Building on Iodine’s trailblazing role in the CDI domain, AwareUM will transform utilization management, propelling hospitals towards heightened productivity and efficiency. As a combined suite of solutions, AwareCDI and AwareUM will bridge the gap in communication between CDI and UM teams, empowering them to master the mid-revenue cycle by capturing accurate and thorough documentation, driving efficient workflows, and strengthening revenue integrity.” AwareUM is powered by Iodine’s AI engine CognitiveML, with nearly 10 years’ experience driving accurate clinical predictions from a rich clinical dataset. By intelligently analyzing all clinical data and documentation in the medical record, AwareUM prioritizes cases for review at the right time and provides transparency and reasoning behind predictions, which enables the capture of correct patient status, streamlines the review process and puts key data at the reviewers’ fingertips. Additionally, AwareUM provides a dedicated hub for all UM work and helps teams communicate effectively with payers to establish medical necessity. AwareUM enables clinicians to work at the top of their license, automating important processes and improving overall efficiency. AwareUM is already deployed in many top U.S. health systems with proven results: “AwareUM has transformed our approach to utilization reviews and allowed our nurses to focus more on understanding the patient’s needs by reducing the amount of time required for administrative tasks. With AwareUM, pertinent documentation and patient information is easily obtained, which has cut our review time by half. In addition, the case prioritization capabilities have helped us identify high-opportunity cases that need to be reviewed first, which has improved our observation rates significantly,” said Sarah Horner, Director of Case Management at Baptist Hospitals of Southeast Texas. With significant expertise across the clinical revenue cycle, in addition to AwareUM, Iodine’s AwareCDI solution has helped more than 900 hospitals capture more than $1.5 billion in earned revenue through more efficient clinical documentation improvement (CDI). Together, AwareUM and AwareCDI streamline revenue cycle management operations, improving reimbursement and enabling providers to focus on the delivery of high quality, patient-centric care. For more information, visit www.iodinesoftware.com/aware-um About Iodine Software Iodine is an enterprise AI company that builds transformative technologies to help healthcare organizations realize the full value of the care provided. Across the revenue cycle, Iodine’s solutions automate complex clinical tasks, create efficiencies and maximize revenue. The company’s powerful, predictive AI/ML engine emulates the judgment of clinicians by interpreting raw clinical data to generate real-time, highly focused, predictive insights. Clinicians and hospital administrators can leverage these insights to dramatically augment the management of care delivery – facilitating critical decisions, scaling clinical workforces through automation, and improving the financial position of health systems. For more information, please visit iodinesoftware.com.

Iodine Software will leverage generative AI to accelerate the impact of its solutions, which includes the 2023 Best in KLAS for Clinical Documentation integrity solution, AwareCDI Iodine Software, a pioneer in healthcare AI technology, today announced an expanded relationship with OpenAI, an AI research and development company. As part of this collaboration, Iodine will gain access to OpenAI’s cutting edge artificial intelligence technologies, including its powerful language model GPT-4. Iodine Software has a deep-rooted history in clinical AI technology, having developed sophisticated, industry leading solutions that enhance financial performance in the mid-revenue cycle.  This collaboration with Open AI allows it to further infuse generative AI and large language models across the breadth of its AwareCDI product suite to improve prediction accuracy, streamline query processes, and develop clinical automation tools that will further stem revenue cycle leakage by ensuring documentation accuracy.  “We are thrilled to collaborate with a fellow pioneer in the field of artificial intelligence,” said William Chan, Iodine CEO and co-founder, “Strategic, fast paced yet cautious innovation has always been our guiding principle. The evolution towards generative AI is a natural next step for us. We are optimistic about its potential impact, yet cautious due to the significant impact on patient care, physician trust and patient reimbursements. Aware of its limitations, such as data hallucinations, we are committed to a responsible approach, ensuring we balance progress with prudence.”  The efficacy of Artificial Intelligence is dependent on data on which the language models are trained. Iodine Software is an industry leader with an unmatched clinical dataset, giving the company an unprecedented opportunity to transform how it supports hospitals across a variety of functions. A recent market analysis of the volatility of CMI validated that Iodine Software’s data cohort is representative of the overall market, which makes it one of  the best and powerful assets for training machine-learning and large language models. By incorporating the latest innovations in large language models, Iodine Software can ensure more specific patient documentation and coding efficiency, increase prediction accuracy, and improve its predictive analytics. These advancements will contribute to streamlining the physician documentation experience, allowing physicians to focus more on patient care, and helping hospitals and health systems to capture more earned revenue from the care they provide. About Iodine SoftwareIodine is an enterprise AI company that is championing a radical rethink of how to create value for healthcare professionals, leaders, and their organizations: automating complex clinical tasks, generating insights and empowering intelligent care. Iodine's powerful predictive engine complements the skills and judgment of healthcare professionals by interpreting raw clinical data to generate real-time, highly focused, predictive insights that clinicians and hospital administrators can leverage to dramatically augment the management of care delivery - facilitating critical decisions, scaling clinical workforces through automation, and improving the financial position of health systems. For more information, please visit iodinesoftware.com. PR Contact: press@iodinesoftware.com.

Key Takeaways: Each year Iodine conducts multiple cohort studies, focused on productivity improvements and overall impacts to performance experienced by clients throughout their journey with Iodine In 2022, 94% of facilities experienced a lift in productivity with Iodine, with the average facility seeing a 136% lift in normalized query volume With Iodine, physician response rates either stay steady, or significantly improve in cases where Interact has also been deployed, even in the face of increased queries Iodine also measures the impact queries have, including CC and MCC capture volumes, CMI, and GMLOS. The vast majority of facilities experienced an improvement in MCC capture with Iodine, with a median of a 27% increase in the number of cases that have an MCC The increase in MCC capture resulted in significant financial impact: an additional $3.5 million in annual reimbursement Iodine Intelligence tackles a new challenge in healthcare’s mid-revenue cycle every month, shedding light on problems and solutions and sharing valuable insights from industry experts. Listen to Episode 15 Impact Amplified: Exploring Success Stores from the Iodine Cohort to learn more. Methodology Iodine's Cohort Studies started as an internal initiative in 2017 in an effort to understand the impact clients saw with AwareCDI and how certain key metrics were trending. Each year Iodine conducts multiple cohort studies, some focus on productivity improvements, others report on overall impacts to performance clients experience throughout their journey with Iodine. Cohort studies are completed by comparing pre-Iodine data as a baseline against the most recent CMS fiscal year's data with Iodine. Every facility for which there is at least two months of baseline data and two months of measurement data is included in the study. Only like months are compared to account for seasonal variety (i.e. January-March of 2021 is compared to January-March of 2022) and for DRG based cohort studies, only that year's CMS DRG tables are used. The intent is to examine: if a CDI team performed at the same level as they did pre-Iodine, what would that performance have been, and what is the difference between that modeled performance and what was actually observed with Iodine. Productivity Iodine examines productivity through two main means, unique case query rate and normalized query volume. Iodine measures both query rate and query volume to provide as complete a picture of CDI performance as possible. Since unique case query rate is an indicator of whether CDI specialists are looking at the right cases, it is possible to have a high query rate by only reviewing those cases that you feel confident you will query, but as a result your query volume will drop. Conversely, you can drive up your query volume by increasing staffing, but that's not very efficient. Examining both query rate and query volume ensures that Iodine has positive impacts on both and is driving as much value for clients as possible. Many health systems use query rate as a measure of success of their CDI program, although methods of calculating this metric can vary between organizations. Iodine examines query rate as a measure of the percent of cases that have been reviewed and resulted in a query - from an efficiency perspective it measures if CDI specialists are looking at the right records. In 2022, the average Iodine client more than doubled their query volume, as compared to their performance immediately preceding the adoption of AwareCDI. Iodine measures normalized query volume as a measure of the overall output from a CDI program, as more queries lead to more accurate documentation which has a variety of downstream affects including accurate reimbursements, quality reporting, and more. Iodine adjusts for changes in CDI staffing over time, and compares the incremental queries sent in the fiscal year 2022 against the baseline period, the year immediately prior to a facility adopting AwareCDI. With Iodine, 80% of facilities saw an improvement to their unique case query rate, with the median hospital experiencing a 42% lift in query rate. So, if prior to Iodine a CDI program was querying 32% of the cases they reviewed, and they experienced the median impact with Iodine, they're now querying 45% of review cases. Higher productivity and more efficient and effective processes enables clients to expand the scope of their programs and accomplish more with their existing staff. One client had a team of 17 CDIS and after implementing Iodine they increased their query rate from 21% to 35% using only half of their staff, enabling the remaining staff to be redeployed to performing retrospective reviews. Other orgs have leveraged the freed up man-hours to increase collaboration with other departments like coding, implement second-level reviews on mortality or PSI cases, and improve job satisfaction as CDI specialists work at top of license. Physician Response Administrative burden is already at an all time high for many physicians, which means the prospect of a CDI department suddenly sending twice as many queries, if not more, can be a daunting one for providers. However, Iodine's cohort studies show that with Iodine physician response rates either stay steady, or significantly improve in cases where Interact has also been deployed. When reviewing and responding to a query is no longer a burden for physicians, response rates and times can improve, even in the face of additional queries. On average, there is an almost 17 hour savings in response time, with CDI specialists waiting 31 hours or less for a physician to answer a query, meaning CDI specialists don't have to spend as much time and energy chasing down responses. The average physician spends 60 seconds or less reviewing and responding to a query, and the median physician response rate for an Iodine client with Interact is 94%. Impact of a Query In addition to lifts in productivity, Iodine also measures the impact those additional queries have, including CC and MCC capture volumes, CMI, and GMLOS, with the theory that as documentation gets addressed, it more accurately reflects the true acuity of the patient population, and as a result these measures naturally go up. The more the productivity of CDI teams improves, the more one can expect MCC capture to increase, as well as CMI and GMLOS to a certain extent. In line with our productivity metrics, the vast majority of facilities, 90%, experienced an improvement in MCC capture with Iodine. On average, their MCC capture volume improved by almost seven percentage points, which ultimately resulted in a 27% increase in the number of cases that have an MCC - more than one out of every four cases. While CMI is a common metric across the industry, especially for CFOs, it's influenced by a wide variety of factors, many of which are outside CDI's control. This includes things like changing patient populations, shifts in med/surg volumes, changes to service line volumes and more. Almost as many facilities experienced a lift in GMLOS as MCC capture (84%). GMLOS is a good indication as to whether or not a hospital is getting credited for how much effort it takes to care for a patient. If a patient is under documented, it will appear that they should have a short hospital stay, and then there can be a gap between expected LOS and actual LOS. Financial Impact Iodine utilizes two different methods for calculating financial impact, a "bottoms up" approach based on the value of a query, and a "top down" approach based on increase in MCC volumes. The bottom's up approach is calculated by examining: what are the number of queries issues by a hospital, how many of those queries are likely to have a financial impact, what was that impact measured in CMI MS-DRG relative weight points. Using this approach, a fictional hospital with 10,000 discharges, a 30/70 med/surg split and a $6,000 base rate would see an additional $2.4 million in appropriate reimburse. Using the top down approach, looking across our entire cohort (which includes everything from hospitals that have been with Iodine for just the minimum two months to hospitals who have been an Iodine client for seven years) the average is $3.5 million in annual additional reimbursements based on improved MCC volumes.